Cover Image

Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck

Jed A. Katzel, Michael P. Fanucchi, William A. Cook, Zujun Li
  • Jed A. Katzel
    Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States | zli@aptiumoncology.com
  • Michael P. Fanucchi
    Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States
  • William A. Cook
    Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States
  • Zujun Li
    Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States

Abstract

Targeted therapies have proven beneficial for patients suffering from a number of different malignancies, including cancers of the head and neck. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor has shown benefit in combination with radiation for untreated patients or as a single agent for patients with platinum resistant disease. Cetuximab is the only targeted agent currently approved by the Federal Drug Administration for the treatment of head and neck cancer. A number of other agents have shown promising initial results including intracellular tyrosine kinase inhibitors, agents targeting vascular endothelial growth factor receptor, as well as other classes of novel therapies. Some of the data supporting the use of targeted therapy, including agents not yet approved in head and neck cancer, will be presented in this review. As our understanding of the cancer cell signaling pathways and novel targeted agents increases, the potential for treatment with reduced toxicity and improved clinical outcomes will become a reality.

Keywords

Epidermal growth factor receptor - Cetuximab - Vascular endothelial growth factor receptor - Head and neck cancer - Targeted therapy

Full Text:

FULL TEXT
Submitted: 2011-12-14 10:51:51
Published: 2011-12-14 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
480

Views:
FULL TEXT
137

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Jed A. Katzel, Michael P. Fanucchi, William A. Cook, Zujun Li

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185